Short Summary
Daewoong Pharmaceutical appealed the rejection of its Indian Patent Application (No.201817048074), which covered a crystalline form of compound c28. The rejection was based on Section 3(d) of the Patents Act, 1970, as the drug was considered known and lacked enhanced therapeutic efficacy. Daewoong sought to introduce additional data demonstrating superior properties like stability and dissolution rates. The High Court accepted the application for additional documents but framed two critical issues: whether this post-filing data is admissible, and if the crystalline form ultimately meets Section 3(d) requirements.
Detailed Summary
of the Paris Local Division of the Unified Patent Court concerning a request for extension of time filed by the Bosch defendants. The judge-rapporteur rejected Bosch's request, finding that a non-redacted version of Valeo's 15 June 2026 filing had been deposited in the CMS simultaneously with the redacted version, and that Bosch had failed to exercise due diligence in accessing it. The court ruled that the deadlines under R.29(d) RdP run from 15 June 2026.
Practitioner Note
This case demonstrates the evidentiary and procedural standards applied in patent matters before Delhi High Court - Orders. Understanding the court's reasoning in Daewoong Pharmaceutical Co. Ltd. vs Controller General Of Patents Designs And Trademarks is valuable context for structuring arguments or assessing risk in similar proceedings.
Related Cases
F- Hoffmann -La Roche Ag & AnrvsZydus Lifesciences Limited
The suit was filed seeking permanent injunction against infringement of two Indian patents related to Pertuzumab (Perjeta). The plaintiffs alleged that the defendant was manufacturing and selling a competing version. However, the court found that the plaintiffs failed to conduct necessary analytical characterization or reverse engineering of the defendant's product as required under Section 104A.
F.Hoffmann-La Roche Ltd.vsMatrix Laboratories Limited
F.Hoffmann-La Roche Ltd. filed a suit seeking permanent injunction against Matrix Laboratories Limited for infringing Indian Patent No.196774, which relates to a pharmaceutical or chemical compound product. The court ultimately disposed of the suit as no further orders were necessary due to the rejection of leave to institute the suit by the Division Bench.
Metro Brands Ltd.vsMetro Footwear
The Plaintiff filed a Commercial IP Suit alleging that the Defendant was infringing its registered trademark 'METRO' and engaging in passing off. The Court found prima facie satisfaction regarding the infringement and granted ad-interim relief.
Vifor International Ltd.vsDr Reddy's Laboratories Limited
The plaintiffs claim infringement of their patent related to drugs comprising 'FERRIC CARBOXYMALTOSE'. The defendant argues that MSN Laboratories is the manufacturer for them.
M/s.Fast ProductsvsG.G.Aqua Industries
M/s.Fast Products filed a suit against G.G.Aqua Industries alleging infringement of its registered trademark 'AQUA FAST' and copyright violation concerning the associated trade dress and artistic label design. The plaintiff sought perpetual injunctions, destruction of infringing goods, and damages. However, on the date of judgment (26.08.2021), the plaintiff failed to appear before the court despite previous proceedings, leading the High Court to dismiss the suit for default.
Dealing with a patent challenge?
Whether it's a Section 3(d) rejection, a post-grant opposition, or a FRAND dispute, Arctic's patent litigation team has handled it. Get a strategy call.
Disclaimer: This page contains an automated summary based on publicly available judicial records. The content is generated for informational purposes only and does not constitute legal advice. Always verify details against the original source judgment before relying on this information for any legal purpose. If you believe any information is inaccurate, please contact us.